Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Cash & Current Investments for 7 consecutive years, with $587.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 63.29% to $587.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $587.5 million through Dec 2025, up 63.29% year-over-year, with the annual reading at $587.5 million for FY2025, 63.29% up from the prior year.
  • Cash & Current Investments hit $587.5 million in Q4 2025 for BridgeBio Pharma, up from $286.3 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $919.1 million in Q1 2021 to a low of $286.3 million in Q3 2025.
  • Historically, Cash & Current Investments has averaged $537.9 million across 5 years, with a median of $520.8 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: surged 141608.27% in 2021 and later plummeted 48.74% in 2023.
  • Year by year, Cash & Current Investments stood at $393.9 million in 2021, then increased by 5.25% to $414.6 million in 2022, then grew by 4.89% to $434.9 million in 2023, then fell by 17.27% to $359.8 million in 2024, then surged by 63.29% to $587.5 million in 2025.
  • Business Quant data shows Cash & Current Investments for BBIO at $587.5 million in Q4 2025, $286.3 million in Q3 2025, and $756.9 million in Q2 2025.